Deep* Company* Huadong Pharmaceutical (000963): Medical and aesthetic business is growing steadily, and multiple pipelines in the pharmaceutical industry have reached important points
East China Pharmaceutical (000963): 1Q24 results are in line with expectations, and the medical aesthetic and industrial microbiology sectors have maintained rapid development
Huadong Pharmaceutical (000963): Steady performance growth pipeline gradually progresses
Shanghai Securities released a research report on April 28 stating that Huadong Pharmaceutical (000963.SZ) was given a purchase rating. The main reasons for the rating include: 1) the pharmaceutical business is growing steadily, and the medical and aesthe
China Galaxy released a research report on April 28 stating that Huadong Pharmaceutical (000963.SZ) was given a recommended rating. The main reasons for the rating include: 1) the main business segments are growing steadily, and the pharmaceutical busines
Huadong Pharmaceutical (000963) 2024 Quarterly Report Review: Steady performance growth pipeline gradually progresses
East China Pharmaceutical (000963): Medical and aesthetic business maintains high growth, innovation, transformation and continuous implementation
SDIC Securities released a research report on April 26 stating that Huadong Pharmaceutical (000963.SZ) was given a purchase rating. The main reasons for the rating include: 1) the continuous development of various businesses and the steady growth of 2024Q
Huadong Pharmaceutical (000963): Achieved a good start in the first quarter, R&D progress accelerated
Huadong Pharmaceutical (000963): Performance growth is steady, and new products are progressing smoothly
East China Pharmaceutical (000963): Q1 Xinckley Aesthetics +23% Continued to monitor the approval progress of the follow-up injection & energy source pipeline
Huadong Pharmaceutical (000963): 1Q24 revenue and profit increased steadily
East China Pharmaceutical (000963): Medical and aesthetic business is growing rapidly, product innovation continues to be implemented
Huadong Pharmaceutical (000963): Performance is in line with expectations, new products are expected to enter the commercialization stage
China Galaxy released a research report on April 21 stating that Huadong Pharmaceutical (000963.SZ) was given a recommended rating. The main reasons for the rating include: 1) the pharmaceutical industry is growing steadily, and innovative drug types are
Huadong Pharmaceutical (000963): Performance is in line with expectations, rapid medical and aesthetic growth & gradual implementation of innovation
East China Pharmaceutical (000963): Innovation and progress during the year were rich, and overseas medical and aesthetic flexibility was released
Great Wall Guorui Securities released a research report on April 18 stating that Huadong Pharmaceutical (000963.SZ) was given a purchase rating. The main reasons for the rating include: 1) steady growth in performance and improvement in overall profitabil
East China Pharmaceutical (000963) Annual Report Review: Improving the layout of regeneration+HA+ botulism pipelines, the ability to contribute to the profitability of the medical and aesthetic business is expected to continue to improve
Depth* Company* East China Pharmaceutical (000963): Medicine and Aesthetics Maintain Rapid Growth, Pharmaceutical Industry Innovation Achievements Gradually Realize
No Data